Sonoma Pharmaceuticals (SNOA) EPS (Diluted) Growth (3y) (2016 - 2026)
Sonoma Pharmaceuticals (SNOA) EPS (Diluted) Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 3.25% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.66% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 11.56% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -35.09% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 13.29% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 36.48% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.12 Mn | -222,819.83 | 2.58 Mn | 75.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.54% |
| Mar 31, 2026 | 96.45% |
| Dec 31, 2025 | 96.63% |
| Sep 30, 2025 | 96.33% |
| Jun 30, 2025 | 49.06% |
| Sep 30, 2024 | 11.57% |
| Jun 30, 2024 | 49.61% |
| Mar 31, 2024 | 89.80% |
| Dec 31, 2023 | 81.04% |
| Sep 30, 2023 | -2,615.76% |
| Jun 30, 2023 | -723.99% |
| Mar 31, 2023 | -3,290.51% |
| Dec 31, 2022 | -1,770.06% |
| Sep 30, 2022 | -1,619.62% |
| Jun 30, 2022 | -124.54% |
| Sep 30, 2021 | 77.55% |
| Jun 30, 2021 | 53.03% |
| Mar 31, 2020 | -78.89% |
| Dec 31, 2019 | -85.73% |
| Sep 30, 2019 | -67.53% |